Optimizing Varicella Vaccination Strategy: A Study on Age and Dose Impacts on Antibody Levels

Overview

Journal Vaccines (Basel)

Date 2025 Jan 24

PMID 39852802

Authors

Qing He

Yang Xu

Yilan Li

Pinting Zhu

Lei Luo

Affiliations

Soon will be listed here.

Abstract

Seropositivity study of Varicella in Healthy Populations in Guangzhou, China. Infection with varicella-zoster virus (VZV) leads to skin and mucous membranes blisters and the complications can be life threatening. A seroepidemiological study conducted from 2020 to 2022 in Guangzhou, China, aimed to evaluate varicella antibody levels. We measured varicella antibody concentrations using an enzyme-linked immunosorbent assay. A total of 3300 people were enrolled in the study. The mean varicella antibody level was 171.2 mIU/mL (95% CI: 158.9, 184.4), with an overall positivity rate of 67.00% (95% CI: 65.37, 68.60). The mean level of those positive subjective was 581.2 mIU/mL (95% CI: 552.3, 611.5). Varicella antibody levels were found to be influenced by age, vaccination dosage, and history of varicella infection. Antibody level increased with age and the number of vaccinations. The antibody induced by the varicella vaccine remained at protective levels for at least 6 years post-vaccination. We recommend two doses of the varicella vaccine for both children and adults and the integration of the varicella vaccine into the national routine immunization program.

References

Shi L, Lu J, Sun X, Li Z, Zhang L, Lu Y . Impact of Varicella Immunization and Public Health and Social Measures on Varicella Incidence: Insights from Surveillance Data in Shanghai, 2013-2022. Vaccines (Basel). 2023; 11(11). PMC: 10674188. DOI: 10.3390/vaccines11111674. View

Coleman S . The association between varicella (chickenpox) and group A streptococcus infections in historical perspective. SAGE Open Med. 2016; 4:2050312116658909. PMC: 4962521. DOI: 10.1177/2050312116658909. View

Macartney K . Long-term protection against varicella with two-dose combination measles-mumps-rubella-varicella vaccine. Lancet Infect Dis. 2019; 19(3):222-223. DOI: 10.1016/S1473-3099(18)30797-7. View

Davies H, McGeer A, Schwartz B, Green K, Cann D, Simor A . Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996; 335(8):547-54. DOI: 10.1056/NEJM199608223350803. View

Ziebold C, von Kries R, Lang R, Weigl J, Schmitt H . Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001; 108(5):E79. View

Gershon A, Breuer J, Cohen J, Cohrs R, Gershon M, Gilden D . Varicella zoster virus infection. Nat Rev Dis Primers. 2016; 1:15016. PMC: 5381807. DOI: 10.1038/nrdp.2015.16. View

Chen H, Liang C, Huang X, Ruan Q, Li Z, Hu X . Vaccination against Varicella Zoster Virus Infection in Less Developed Regions of Guangdong, China: A Cross-Sectional Serosurveillance Study. Vaccines (Basel). 2023; 11(3). PMC: 10056728. DOI: 10.3390/vaccines11030494. View

Baxter R, Ray P, Tran T, Black S, Shinefield H, Coplan P . Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics. 2013; 131(5):e1389-96. DOI: 10.1542/peds.2012-3303. View

Laing K, Ouwendijk W, Koelle D, Verjans G . Immunobiology of Varicella-Zoster Virus Infection. J Infect Dis. 2018; 218(suppl_2):S68-S74. PMC: 6151075. DOI: 10.1093/infdis/jiy403. View

10.

Marin M, Leung J, Anderson T, Lopez A . Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019. J Infect Dis. 2022; 226(Suppl 4):S392-S399. DOI: 10.1093/infdis/jiac221. View

11.

Laupland K, Davies H, Low D, Schwartz B, Green K, McGeer A . Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics. 2000; 105(5):E60. DOI: 10.1542/peds.105.5.e60. View

12.

Marin M, Marti M, Kambhampati A, Jeram S, Seward J . Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 2016; 137(3):e20153741. DOI: 10.1542/peds.2015-3741. View

13.

Feng H, Zhang H, Ma C, Zhang H, Yin D, Fang H . National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis. Lancet Reg Health West Pac. 2023; 32:100639. PMC: 9918754. DOI: 10.1016/j.lanwpc.2022.100639. View

14.

Hwang J, Kim Y, Lee K, Shin O, Gim J, Shin Y . Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus. Hum Vaccin Immunother. 2023; 19(1):2210961. PMC: 10294754. DOI: 10.1080/21645515.2023.2210961. View

15.

Lebo E, Kruszon-Moran D, Marin M, Bellini W, Schmid S, Bialek S . Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010. Open Forum Infect Dis. 2015; 2(1):ofv006. PMC: 4438887. DOI: 10.1093/ofid/ofv006. View

16.

Zhan S, Yang Y, Fu C . Public's early response to the novel coronavirus-infected pneumonia. Emerg Microbes Infect. 2020; 9(1):534. PMC: 7067171. DOI: 10.1080/22221751.2020.1732232. View

17.

Tommasi C, Breuer J . The Biology of Varicella-Zoster Virus Replication in the Skin. Viruses. 2022; 14(5). PMC: 9147561. DOI: 10.3390/v14050982. View

18.

Varela F, Pinto L, Scotta M . Global impact of varicella vaccination programs. Hum Vaccin Immunother. 2018; 15(3):645-657. PMC: 6605725. DOI: 10.1080/21645515.2018.1546525. View

19.

Shapiro E, Marin M . The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States. J Infect Dis. 2022; 226(Suppl 4):S425-S430. DOI: 10.1093/infdis/jiac299. View

20.

Pawaskar M, Gil-Rojas Y, Parellada C, Rey-Velasco A, Beltran C, Prieto E . The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008-2019. Vaccine. 2022; 40(35):5095-5102. DOI: 10.1016/j.vaccine.2022.07.012. View